Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 6/20 | 0.40 |
| ▸ | DRD2 | P14416 | 2/20 | 0.39 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.38 |
| ▸ | CKS1B | P61024 | 1/20 | 0.37 |
| ▸ | SKP1 | P63208 | 1/20 | 0.37 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6093753 | 0.97 | FAAH (0.46) | DYRK1AFAAHBRD4DRD2CNR2 | |
| SCHEMBL6096304 | 0.94 | BRD4 (0.38) | DYRK1AFAAHBRD4DRD2CKS1B | |
| SCHEMBL1230929 | 0.91 | DYRK1A (0.43) | DYRK1AFAAHBRD4DRD2CNR2 | |
| SCHEMBL4790929 | 0.90 | IDO1 (0.37) | DYRK1AFAAHBRD4CNR2SIGMAR1 | |
| SCHEMBL6094861 | 0.88 | TLR7 (0.47) | DYRK1ADRD2CNR2 | |
| SCHEMBL6096040 | 0.87 | TLR7 (0.43) | DYRK1AFAAHDRD2PIM1PIM3 | |
| SCHEMBL1233520 | 0.86 | ALDH1A1 (0.38) | DYRK1ABRD4DRD2CKS1BSKP1 | |
| SCHEMBL6096601 | 0.85 | TLR7 (0.48) | DYRK1AFAAHBRD4DRD2PIM1 | |
| SCHEMBL12888445 | 0.85 | TLR7 (0.42) | DYRK1ASIGMAR1CKS1BSKP1SKP2 | |
| SCHEMBL6095557 | 0.82 | DRD2 (0.40) | DYRK1AFAAHBRD4DRD2CKS1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7098221-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-08-29 | — | — | US | disclosed |
| US-20050282854-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2005-12-22 | — | — | US | disclosed |
| US-6969722-B2 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-11-29 | — | — | US | disclosed |
| US-6903113-B2 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-06-07 | — | — | US | disclosed |
| US-6878719-B2 | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2005-04-12 | — | — | US | disclosed |
| US-20040186128-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-09-23 | — | — | US | disclosed |
| EP-1453829-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-08 | — | — | EP | disclosed |
| EP-1451187-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| EP-1451186-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES | 3M Innovative Properties Company (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040157879-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-08-12 | — | — | US | disclosed |
| US-20030195209-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-16 | — | — | US | disclosed |
| US-20030186949-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-10-02 | — | — | US | disclosed |
| US-20030176458-A1 | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-09-18 | — | — | US | disclosed |
| US-20030162806-A1 | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-28 | — | — | US | disclosed |
| WO-2003050119-A2 | UREA SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050117-A1 | SULFONAMIDO SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| WO-2003050118-A1 | AMIDE SUBSTITUTED IMIDAZOPYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2003-06-19 | — | — | WO | disclosed |
| US-6545017-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6545016-B1 | Inducing cytokine biosynthesis; treating a viral and neoplastic diseases | 3M INNOVATIVE PROPERTIES COMPANY | 2003-04-08 | — | — | US | disclosed |
| US-6525064-B1 | Immune response modifiers; can induce the biosynthesis of various cytokines; | 3M INNOVATIVE PROPERTIES COMPANY | 2003-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186128-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | DYRK1A 4579/4885FAAH 2542/4885BRD4 57/4885 |
| US-20030176458-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | DYRK1A 4311/4885FAAH 4425/4885BRD4 463/4885 |
| US-20030195209-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | DYRK1A 4311/4885FAAH 4425/4885BRD4 463/4885 |
| US-20050282854-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | DYRK1A 4579/4885FAAH 2542/4885BRD4 57/4885 |
| US-20040157879-A1 | Urea substituted imidazopyridines | EIF2AK2, UMPS, IRF3 | DYRK1A 4311/4885FAAH 4425/4885BRD4 463/4885 |
| US-20030162806-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | DYRK1A 4579/4885FAAH 2542/4885BRD4 57/4885 |
| US-20030186949-A1 | Amide substituted imidazopyridines | IRF3, EIF2AK2, IFNG | DYRK1A 4579/4885FAAH 2542/4885BRD4 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.